Equities

Can Fite Biopharma Ltd

Can Fite Biopharma Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (ILa)10.00
  • Today's Change0.00 / 0.00%
  • Shares traded926.89k
  • 1 Year change-57.45%
  • Beta1.1569
Data delayed at least 20 minutes, as of Jun 23 2022 15:24 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Can Fite Biofarma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. It's technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.

  • Revenue in ILS (TTM)3.10m
  • Net income in ILS-53.72m
  • Incorporated1994
  • Employees8.00
  • Location
    Can Fite Biopharma Ltd10 Bareket Street, Kiryat Matalon,P.O. Box 7537PETAH TIKVA 4951778IsraelISR
  • Phone+972 39241114
  • Fax+972 39249378
  • Websitehttp://www.canfite.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Cannassure Therapeutics Ltd34.03m-16.52m18.39m----3.62--0.5404-0.1998-0.19980.41140.06131.077.837.21---52.07-68.89-157.82-99.15-20.30---48.55-232.190.3716-21.350.7343--872.98--42.12------
Univo Pharmaceuticals Ltd-100.00bn-100.00bn24.39m12.00--0.6533----------1.22-----------40.93---53.86-------95.670.7772--0.4718--25.38170.24-3,522.40--428.61--
Cannomed Medical Cannabis Industries Ltd658.00k-13.43m25.05m----1.02--38.06-0.1351-0.13510.00680.24620.01453.010.2826---27.64-25.38-39.16-34.72-1,503.34---1,912.16-183.481.76-22.170.3003---96.33---52.41--240.27--
Nextage Therapeutics Ltd91.00k-8.09m31.69m--------348.27-0.3108-0.31080.0035-0.00970.0218--7.00---190.19-113.43-454.09-146.1917.5860.50-8,717.58-2,970.23---36.520.723---52.3626.5849.34------
Hadasit Bio Holding Ltd.0.0028.36m37.82m16.001.330.57581.33--2.562.560.005.920.00------52.6221.4254.4430.52------7,536.18----0.00-------9.11---57.02--
BioLight Life Sciences Ltd3.00k382.00k42.86m18.00117.500.7061--14,286.650.080.080.000713.310.00005--0.0094---0.5256-1.43-0.5529-1.55-----11,300.00-83.09---4.160.00720.00-90.32-73.05103.06--11.09--
Kadimastem Ltd0.00-26.28m48.94m32.00--3.07-----1.15-1.150.000.45710.00-------137.81-194.59-549.63-8,290.20-------17,319.74---10.040.2789-------21.03--3.15--
Can Fite Biopharma Ltd3.10m-53.72m80.90m8.00--1.97--26.09-0.087-0.0870.00490.05020.0595--0.916387,671.40-86.12-108.70-102.79-144.60-----1,447.36-638.09---100.320.00--11.8038.07-0.3101--1.07--
GFC Green Fields Capital Ltd0.008.22m101.53m2.0012.360.697812.35--0.80930.80930.0014.330.00------4.382.145.812.72------------0.00------1,213.55-7.16----
Tikun Olam Cannbit Pharmaceuticals Ltd37.03m-32.65m105.25m----0.6645--2.84-0.7782-0.77820.88463.520.19262.7015.73---17.70-22.28-20.03-25.63-20.07---91.89-172.641.21-25.880.1193--70.97--0.8804------
Data as of Jun 23 2022. Currency figures normalised to Can Fite Biopharma Ltd's reporting currency: Israeli Shekel ILS

Institutional shareholders

0.34%Per cent of shares held by top holders
HolderShares% Held
IBI Mutual Funds Management (1978) Ltd.as of 28 Feb 20222.76m0.34%
Data from 28 Feb 2022 - 28 Feb 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.